Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kirsten Bell-Burdett"'
Autor:
Alfredo Falcone, Chiara Cremolini, Jing Lyu, Dominic T. Moore, Daniele Rossini, Richard M. Goldberg, Anastasia Ivanova, Yingmiao Liu, Ace J. Hatch, Alexander B. Sibley, Kelli Hammond, Andrew B. Nixon, Federica Marmorino, Federico Innocenti, Hanna K. Sanoff, Mark D. Starr, Kouros Owzar, John C. Brady, Kirsten Bell Burdett, Michael S. Lee
Publikováno v:
Molecular Cancer Therapeutics. 19:2146-2154
Regorafenib is a tyrosine kinase inhibitor approved by the FDA for the treatment of patients with chemotherapy refractory metastatic colorectal cancer (mCRC). Regorafenib inhibits signaling through multiple receptors associated with angiogenesis, met
Autor:
Víctor A. Arrieta, Craig Horbinski, Rimas V. Lukas, Jawad Fares, Maciej S. Lesniak, Theresa V. Strong, Karen S. Aboody, Jana Portnow, Sean Grimm, David T. Curiel, Hui Zhang, Catalina Lee-Chang, Roger Stupp, Christina Amidei, Ann K. Adams, James P. Chandler, Priya Kumthekar, Matthew C. Tate, Sean Sachdev, Ilya V. Ulasov, Markella Zannikou, Atique Ahmed, Kirsten Bell Burdett, Adam M. Sonabend, Charles D. Hébert, Irina V. Balyasnikova, Jason Miska
Publikováno v:
The Lancet. Oncology. 22(8)
Summary Background Malignant glioma is the most common and lethal primary brain tumour, with dismal survival rates and no effective treatment. We examined the safety and activity of NSC-CRAd-S-pk7, an engineered oncolytic adenovirus delivered by neur
Autor:
Heather A. Lankes, Michael J. Birrer, Robert A. Burger, Yingmiao Liu, David M. O'Malley, Matthew P. Boente, Wei Deng, Andrew B. Nixon, Jamie N. Bakkum-Gamez, J. Chris Brady, Kouros Owzar, Krishnansu S. Tewari, Kirsten Bell Burdett, David Tritchler, Mark D. Starr, Angeles Alvarez Secord, Alexander B. Sibley, Herbert Hurwitz, Keiichi Fujiwara, Robert S. Mannel, Heidi J. Gray
Publikováno v:
Clin Cancer Res
Purpose: GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demon